#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Adrenoleukodystrophy Leiomyosarcoma recurrent Fontan procedure Becker's muscular dystrophy Haemophilia B without inhibitors Oesophageal atresia Angelman's syndrome Rectal cancer Immunoglobulin G4 related disease Ehlers-Danlos syndrome Squamous cell carcinoma of the vulva Oesophageal adenocarcinoma stage II Pyruvate dehydrogenase complex deficiency Acquired ATTR amyloidosis Squamous cell carcinoma of the hypopharynx More trials…

    Learn about Rare Diseases

    Von Willebrand’s disease – Basic Information Haemophilia – Treatment Burkitt’s lymphoma – Life with Disease Marfan’s syndrome – Trials in Disease Atypical haemolytic uraemic syndrome – Treatment Pituitary-dependent Cushing’s syndrome – Diagnostics Angiosarcoma recurrent – Treatment Glomerulonephritis membranous – Trials in Disease Adrenogenital syndrome Mucous membrane pemphigoid – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Vepdegestrant Eftrenonacog Alfa Relacorilant Aficamten ANTI-GD2-800CW Betula Verrucosa (108) Danazol Roxithromycin Pegipanermin Efgartigimod Alfa Tremelimumab Fludarabine Phosphate Ph. Eur. PEGVISOMANT SEVUPARIN Topiramate Cenerimod Riociguat Timothy Grass Pollen Extract Cebsulfase Alfa Isaralgagene Civaparvovec More therapies…

    Learn about Your Condition

    Thrombocytopenia Constipation Haemodialysis Androgenetic alopecia T-cell type acute leukaemia Neonatal asphyxia Appendicitis perforated Corticobasal degeneration Epidermolysis bullosa Cancer fatigue Renal transplant Left ventricular dysfunction Syphilis Food allergy Hand fracture More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Paoli-Calmettes Cancer Centre

Institut Paoli-Calmettes Cancer Centre

2ok Bnrbrivuz Dl Swmpoz Mhqvckkperb Bn 1cxc Maxmjfzrqd 1tymfd Ffauhf

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Obinutuzumab
    • Pirtobrutinib
    • Venetoclax
    Austria Belgium Czechia Denmark Finland France +8

  • Study on Reducing Side Effects of Lutetium (177Lu) Oxodotreotide in Patients with Advanced Midgut Neuroendocrine Tumors

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Small intestine neuroendocrine tumour
    Investigated Drugs:
    • Lutetium (177Lu) Oxodotreotide
    France Spain

  • Study on the Effectiveness of Etoposide, Carboplatin, and Cisplatin in Patients with Localized Digestive Neuroendocrine Carcinomas

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Etoposide
    France

  • Study on Pembrolizumab for Patients with Early Triple-Negative Breast Cancer Responding Well to Initial Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Pembrolizumab
    Belgium France

  • Study of olaparib and chemotherapy combination in stage III breast cancer patients with HER2-negative, hormone receptor impaired or deficient disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Doxorubicin
    • Capecitabine
    • Carboplatin
    France The Netherlands

  • Study on Axatilimab and Corticosteroids for Initial Treatment of Chronic Graft-Versus-Host Disease in Patients

    Recruiting

    3 1 1
    Investigated Drugs:
    • Axatilimab
    • Methylprednisolone
    • Prednisone
    Austria Denmark France Germany Ireland Italy +2

  • Study Comparing Ivonescimab to FOLFOX Drug Combination for Patients with Advanced Biliary Tract Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Calcium Levofolinate
    • Calcium Folinate
    • Fluorouracil
    France

  • Study on the Safety and Effectiveness of SMART101 for Patients Undergoing Stem Cell Transplantation for Blood Cancers

    Recruiting

    2 1 1
    Investigated Diseases:
    • Allogenic stem cell transplantation
    • Haematological malignancy
    Investigated Drugs:
    • Allogeneic T-Cell Precursors, Mobilized Peripheral Blood-Derived, Ex Vivo Cultured
    France Italy

  • Study on Stopping Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia Who Are Responding to Treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Azacitidine
    • Venetoclax
    France

  • Study on Glofitamab, Venetoclax, and Zanubrutinib for Patients with Untreated or Relapsed High-Risk Mantle Cell Lymphoma

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Glofitamab
    • Obinutuzumab
    • Venetoclax
    Belgium France
Previous Page
1 … 6 7 8 9 10 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!